Brain-derived neurotrophic factor (BDNF) and its receptor TrkB play an important function in neuronal development and synaptic plasticity. Recently we have established that cyclothiazide (CTZ) is a novel convulsant drug inducing robust epileptiform activity in hippocampal neurons both in vitro and in vivo. However, the molecular mechanisms underlying such convulsant action of CTZ are unknown. Here, we investigated potential roles of BDNF-TrkB signaling pathway in the CTZ-induction of epileptiform activity. In anaesthetized rats, CTZ dose-dependently induced epileptiform activity characterized by progressing of multiple peaks of population spikes, spontaneous spiking events, and synchronized epileptiform bursts. Pre-injection of a receptor tyrosine kinase inhibitor K252a or a specific antibody for TrkB receptors before intracerebroventricular injection of CTZ significantly suppressed the epileptiform activity induced by CTZ. Similarly, in cultured hippocampal pyramidal neurons, pre-treatment with CTZ together with K252a or TrkB-receptor antibody also inhibited the CTZ-induction of epileptiform activity. Furthermore, we demonstrated that acute application of K252a in hippocampal cultures inhibited epileptiform bursts and action potential firing. We conclude that activation of BDNF-TrkB signaling pathway is fundamentally important during the CTZ-induction of epileptiform activity both in vitro and in vivo.
Introduction
Brain-derived neurotrophic factor (BDNF) and its specific receptor TrkB are critically involved in neural development and synaptic plasticity (Huang and Reichardt, 2001; Poo, 2001; Lu, 2003) . BDNF-TrkB signaling pathway has also been found to play an important role in epileptogenesis (Binder et al., 2001) . BDNF release depends on neuronal activity (Goodman et al., 1996; Balkowiec and Katz, 2000) . Epileptiform activity increases the expression level of BDNF mRNA as well as proteins (Gall et al., 1991; Nawa et al., 1995; Elmer et al., 1998; He et al., 2002) . In BDNF heterozygous (þ/À) mice, the kindling rate of epileptiform activity is decreased twofold compared to wild type controls (Kokaia et al., 1995) . In addition, in vivo studies have demonstrated that infusion of BDNF into the adult rat hippocampus results in seizures (Scharfman et al., 2002) . The effect of BDNF is generally believed to be mediated by the activation of TrkB receptors. Transgenic overexpression of a truncated dominant negative form of TrkB receptors interferes with epileptiform activity in the kainic acid (KA) model of epilepsy in mice (Lahteinen et al., 2002) . Recent work reported that conditional knockout of TrkB receptor, but not BDNF, significantly suppresses the formation of epileptiform activity in the kindling model of epilepsy . While substantial evidences suggest that BDNF-TrkB signaling is proepileptic, some studies also suggest possible antiepileptic effects of neurotrophins including BDNF (Simonato et al., 2006 ). The precise mechanisms of BDNFTrkB signaling during epileptogenesis are not fully understood yet. Here, we employ a novel epilepsy model recently established in our lab to further investigate the functional role of BDNF-TrkB in epileptogenesis.
The convulsant drug we identified is cyclothiazide (CTZ). CTZ has long been known as an AMPA receptor desensitization blocker and thus prolongs glutamate excitatory responses (Partin et al., 1993; Trussell et al., 1993; Yamada and Tang, 1993; Zorumski et al., 1993) . CTZ also increases presynaptic glutamate release (Diamond and Jahr, 1995; Bellingham and Walmsley, 1999; Ishikawa and Takahashi, 2001 ). In addition, we have demonstrated that CTZ can directly inhibit GABA A receptor function, acting as a GABA A receptor blocker (Deng and Chen, 2003) . Furthermore, we demonstrated that CTZ induces epileptiform bursts in hippocampal neurons both in vitro and in vivo (Qi et al., 2006a) , partly due to downregulation of tonic GABA A receptor function (Qi et al., 2006b ). Thus, the opposite actions of CTZ on glutamatergic and GABAergic neurotransmission provide a unique model for studying mechanisms of epileptogenesis. Here, we report that BDNF-TrkB signaling pathway is critically involved in the CTZ-induction of epileptiform bursts. Blocking TrkB receptors significantly reduced epileptiform bursts induced by CTZ in hippocampal neurons both in vivo and in vitro. Patch clamp recordings also revealed a significant block of epileptiform bursts and action potential firing after acutely inhibiting receptor tyrosine kinases with K252a. Our studies suggest that BDNF-TrkB signaling is likely a common pathway during epileptogenesis that mediates the transition from individual action potentials to epileptiform bursts.
Materials and methods

Animal preparation
In vivo experiments were performed on urethane anaesthetized (1.2 g kg À1 , i.p.) male Sprague Dawley rats (280-350 g). The level of anaesthesia was assessed by the absence of a withdrawal reflex, and additional anaesthetic (urethane, 0.2-0.6 mg kg
À1
, i.p.) was administered as necessary. Body temperature was maintained at 37 AE 0.5 C with a Harvard Homoeothermic Blanket (Harvard Apparatus Limited, Kent, UK). Animals were housed in a regulated environment (21 AE 1 C) with a 12 h light-dark cycle, and food and water available ad libitum. All experiments were approved by the local committees of Laboratory Animals, Fudan University and Chongqing Technology and Business University and carried out in accordance with Chinese National Science Foundation animal research regulation. At the end of experiments, animals were euthanized with overdose of urethane.
Animals were prepared as previously described (Qi et al., 2006a; Wang et al., 2006) . Animals had their lateral tail vein cannulated for drug administration and were mounted in a stereotaxic frame. An incision was made in the midline of the head to expose the top part of the skull. For implantation of the i.c.v. cannula, a drill hole was made on the skull above the left side of the lateral ventricle (0.3 mm posterior to bregma, 1.3 mm lateral to the midline). A guide cannula (Bilaney Consultants Ltd, TN, USA) was then placed 4 mm below the skull surface for drug delivery, and secured by the dental cement.
Recording and data acquisition
For recording and stimulating, a large burr hole was made in the left side of the incised skull above the hippocampal area, and the dura was pierced and removed. The stereotaxic coordinates were determined from the stereotaxic atlas of the rat brain (Paxinos and Watson, 1986) . A concentric bipolar metal electrode (Harvard Apparatus Ltd, Kent, UK) was placed close to CA3 region (3.8-4.5 mm posterior to bregma, 3.5-4.0 mm lateral to the midline, and 3.0-3.8 mm below the brain surface) in order to stimulate the CA3 pyramidal cell layer and/or Shaffer collateral pathway. For recording in the CA1 pyramidal cell layer, a tungsten electrode (0.5 MU, WPI, Stevenage, UK) was placed 3.5-4.2 mm posterior to bregma, 2.0-3.0 mm lateral to the midline. The depth of the recording electrode was approximately 2.0-2.5 mm below the brain surface as determined by the sudden change of the electrical noise and the shape of the evoked field excitatory postsynaptic potential (fEPSP) and population spike (PS). For CA3-CA1 Shaffer collateral stimulation, a constant current generator passed a square-wave pulse (0.2 ms in duration) through the stimulating electrode (test pulse). Test pulses evoked a positive excitatory postsynaptic field potential in the CA1 with a population spike superimposed as a negative deflection on the rising phase. After initial recording and stimulating tests, both electrodes Fig. 1 . CTZ-induced progressive epileptiform bursts including evoked multiple population spikes and spontaneous seizure bursts in hippocampal CA1 pyramidal region in in vivo recordings. (A) Typical recordings showing that the evoked population spikes recorded from CA1 pyramidal layer in urethane-anaesthetised rats transformed from single peak at control condition to double, triple, and quadruple multiple peaks (the extra peaks are indicated by hollow arrows) after CTZ injection (5 mmol, 5 ml, i.c.v.) (C indicates the stimulus artefact). The time in parenthesis indicates the latency of the multiple PS peaks after CTZ injection. (B) Spontaneous discharges recorded in the same rat as in (A). Before CTZ injection, the base line activity was usually silent in CA1 pyramidal cells (a). After CTZ injection, some high amplitude spontaneous spiking activity appeared, first in continuous but individual mode (b), and then became partially grouped (c), and finally formed highly synchronized epileptiform bursts (d). Each large burst was consisted of many smaller bursts of discharges.
were adjusted to obtain the maximal evoked EPSP and population spike amplitude. The PS amplitude was used as a measure of postsynaptic responses, with a stimulation intensity set at the current required to produce the maximal response, predetermined by input-output curves. During experiments, CA1 pyramidal cell excitability was sampled every 60 s by a test pulse. In-between stimulations, the baseline activity was recorded for evidence of spontaneous activity. The electrophysiological signals were amplified (200 times) and filtered (0.3-3 kHz) using a NeuroLog System (Digitimer Ltd., Hearts, UK) and visualised and stored in a PC computer through an A-D converter, CED 1401 micro (Cambridge Electronic Design, Cambridge, UK). Once both electrodes were in the right place, the fEPSPs and PS were monitored for at least 30 min (20 min of baseline recording without stimulation and 10 min evoked EPSP/PS recording) until a stable recording was achieved. Following a 30 min recorded baseline of all responses, drugs or vehicles were administered i.c.v. (intracerebral ventricle) at volume of 5 ml via the pre-implanted guide cannula into the lateral ventricle. Pharmacologically induced epileptiform activity was monitored for 3 h after either CTZ or vehicle DMSO injection by observing changes of evoked potentials transform from single PS into multi-peaked display and spontaneous epileptiform burst activity in CA1 pyramidal neurons (Wheal et al., 1998) . The anaesthetic level was monitored and maintained throughout the course of experiments, in particular, after convulsant drug administration. On some occasions, the brain was taken for histological validation of the injection and recording/stimulating sites.
Animals were divided into following 10 groups for drug test:
Group 1: DMSO control;
Groups 2 and 3: CTZ 1 mmol and 5 mmol;
Group 4: K252a alone;
Group 5-7: K252a 30, 60 and 180 min pre-treatment plus CTZ 5 mmol;
Group 8: TrkB antibody alone;
Groups 9and 10: TrkB antibody 30 and 60 min pre-treatment plus CTZ 5 mmol.
Analysis of data
Epileptiform activity within CA1 pyramidal cells was analyzed offline using Spike2 (an analysing program for CED 1401, Cambridge, UK) and specific scripts designed for this study with Spike2. Multiple population spike peaks typically represent epileptiform evoked responses (Traub et al., 1994) . Therefore, the evoked multiple population spike peaks, defined as the negative deflection peaks superimposed on the rising phase of the evoked EPSPs, were counted and the latency for evoking these multiple population spike peaks was analyzed. The spontaneous high amplitude spiking events (>0.5 mV) were defined as those containing 1 or 2 spikes occurring at low frequency (<1 Hz) (Fig. 1) . The latency for spontaneous high amplitude spikes was recorded from the usual 'silent' baseline. The highly synchronized bursting activity was defined, in distinguishing from spontaneous spiking events, as having high frequency multiple high amplitude spikes (>0.5 mV) with an initial interspike interval of less than 0.2 s, a minimum of 5 spikes, and burst duration over 1 s.
Group data were expressed as the mean AE SEM. Across groups of data, statistical significance between means was determined using one-way ANOVA with Tukey HSD post hoc analysis (GraphPad Prism, GraphPad Software Inc.). Comparisons within a group used a paired two-tail t test. Significance level was set at P < 0.05.
Histology
At the end of experiments Pontamine Sky Blue (1 ml) was injected though the pre-implanted cannula to verify the cannula position before the brain was removed and fixed in 10% formal saline. Frozen sections (80 mm) were cut and stained with Neutral Red. The Pontamine Sky Blue marked sites and the stimulating and recording electrode tracks were visualised and mapped onto standard sections of the brain (Paxinos and Watson, 1986) . For those successfully recovered recording/ stimulating tracks, they were all localised in the right place in CA1 pyramidal cell layer and CA3 area, respectively, and the marked cannula sites were in the lateral ventricle.
In vitro electrophysiology
The detailed in vitro electrophysiology protocol has been described previously (Qi et al., 2006a,b) . Briefly, whole-cell recordings were performed on cultured hippocampal neurons from CA1 to CA3 region in current clamp mode using a MultiClamp 700A amplifier (Axon Instrument). Patch pipettes were pulled using (c). **, P < 0.01 and ***, P < 0.001. Sutter P-97 pipette puller and the final resistance of pipettes was 3-6 MU. The recording chamber was continuously perfused with a bath solution containing 128 mM NaCl, 30 mM Glucose, 25 mM HEPES, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , pH 7.3 adjusted with NaOH. The pipette solution contained 125 mM KGluconate, 10 mM KCl, 2 mM EGTA, 10 mM HEPES, 10 mM Tris-phosphocreatine, 4 mM MgATP, 0.5 mM Na 2 GTP, pH 7.3 adjusted with KOH. The series resistance was typically 10-20 MU and partially compensated by 30-50%. The membrane potential was held around À70 mV in current clamp recordings. Data were acquired using pClamp 9 software, sampled at 2-10 kHz, and filtered at 1 kHz. Off-line analysis was done with Clampfit 9 software (Axon Instrument). An epileptiform burst is defined by at least 5 consecutive action potentials overlaying on top of a large depolarization shift (>10 mV). When quantifying percentage of neurons showing epileptiform activity, the criteria is at least 4 repeated epileptiform bursts occurring during 20 min of recording. Pyramidal shape neurons were selected for recordings.
Drugs and solutions
The following drugs were freshly made before each experiment: Cyclothiazide (1 M or 0.2 M in DMSO for in vivo injection) and K252a (0.25 M in DMSO for in vivo injection) were purchased from Tocris (Northpoint, Bristol); anti-TrkB mouse antibody (TrkB antibody) was from BD Biosciences (San Jose, California); Pontamine sky blue dye (20 mg ml À1 ; BDH, Poole) was dissolved in 0.5 M sodium acetate; Urethane (25%; Sigma Aldrich Chemical Co., Poole, Dorset) was dissolved in distilled water.
Results
CTZ-evoked epileptiform activity in hippocampal CA1 neurons in vivo
In anaesthetised rats, recordings were made from CA1 pyramidal cell layer with stimulating rate at 1/60 s, if applied, in the area of CA3. In control condition, only a single PS was embedded on top of the evoked EPSP and there was no spontaneous activity in the baseline (Fig. 1Aa and Ba). Microinjection of CTZ (5 mmol in 5 ml DMSO) into left-side lateral ventricle induced multiple evoked PS peaks in a time-dependent manner ( Fig. 1Ab-Ad) . Furthermore, after w40 min of CTZ injection, spontaneous high amplitude spikes appeared in the baseline, which gradually formed grouped spikes and finally became highly synchronized epileptiform bursts (Fig. 1Bb-Bd) . Interestingly, the evoked multiple peaks always appeared first after CTZ injection, before the occurrence of high amplitude spontaneous spikes, although sometimes the evoked 4 peaks appeared concurrently with the spontaneous spikes. We also noted that after CTZ injection, it usually took 1-2 h for the initial spontaneous spikes to be gradually transformed into highly synchronized epileptiform bursts (Fig. 1B) . After the bursting activity occurred, it was usually impossible to evoke EPSPs and PSs.
We investigated the potent epileptogenic effect of CTZ through i.c.v. administration at two different doses, 1 mmol and 5 mmol, respectively. Injection of higher dose of CTZ (5 mmol) showed an increased probability and shortened latency in inducing epileptiform bursts (Fig. 2) . CTZ injection resulted in double PS peaks in all rats tested (n ¼ 10 at 1 mmol and n ¼ 12 at 5 mmol), and triple PS peaks in 8 out of 10 (80%) rats at 1 mmol and 12 out of 12 (100%) rats at 5 mmol dose (Fig. 2Aa) . CTZ injection at both 1 and 5 mmol doses induced spontaneous high amplitude spikes in all rats tested (Fig. 2Ab) . In contrast, 1 mmol CTZ injection only induced synchronized epileptiform bursts in 5 out of 10 (50%) rats, whereas 5 mmol CTZ injection induced epileptiform bursts in 10 out of 12 (83%) rats (Fig. 2Ac) . The latency for evoking triple PS peaks was 51.9 AE 7.7 min (n ¼ 8) after 1 mmol CTZ injection, and greatly shortened to 22.2 AE 2.3 min (n ¼ 12) after 5 mmol CTZ injection ( Fig. 2Ba , P < 0.001, Student's t test). The latency for inducing spontaneous high amplitude spikes was 51.2 AE 1.6 min (n ¼ 10)
after 1 mmol CTZ injection, and 39.9 AE 2.8 min (n ¼ 12) after 5 mmol CTZ injection ( Fig. 2Bb , P < 0.01). Furthermore, the latency for inducing synchronized epileptiform bursts was 102.9 AE 8.1 min (n ¼ 5) after 1 mmol CTZ injection, and 85.5 AE 8.2 min (n ¼ 10) after 5 mmol CTZ injection ( Fig. 2Bc , P > 0.2). Overall, the latency for evoking epileptiform activity was shortened at 5 mmol group in comparison with the 1 mmol group, indicating that the epileptogenic effect of CTZ is dose-dependent. For control experiments, DMSO (5 ml, i.c.v.), the vehicle for dissolving CTZ, was found not to induce any multiple PS peaks nor spontaneous spikes or synchronized bursts in 3 h recording period in all rats tested (n ¼ 6) ( Fig. 2A) .
Effects of K252a on CTZ-induced epileptiform bursts in hippocampal CA1 neurons in vivo
To test the hypothesis that BDNF-TrkB receptor signaling pathway mediates the CTZ-induction of epileptiform bursts, we first employed K252a, a non-competitive inhibitor for receptor tyrosine kinases including TrkB receptors, to investigate its effect in hippocampal CA1 neurons (Kang et al., 1997; Zhu and Roper, 2001; Cheng and Yeh, 2003) . K252a was administered (250 mM, 5 ml, i.c.v.) either 30 min (n ¼ 6), 1 h (n ¼ 9), or 3 h (n ¼ 5) prior to CTZ injection (5 mmol). In 30 min pre-injection group, K252a almost completely blocked CTZ-induced epileptiform bursts, but the 60 min pre-injection group showed persistent spontaneous spikes after longer delay following CTZ injection (Fig. 3A-C) . The percentage of animals showing triple PS peaks, spontaneous spikes, and synchronized bursts after K252a and CTZ injection was summarized in the middle columns of Fig. 4 . For control experiments, K252a injection alone did not induce any epileptiform activity as expected. Injection of K252a 30 min before CTZ injection suppressed triple PS peaks and epileptiform bursts in all 6 rats tested, while only 1 out of 6 rats showed spontaneous spikes after a prolonged latency of >100 min following CTZ injection (Fig. 4, middle columns) . If K252a was injected 60 min or 180 min before CTZ injection, most animals showed triple PS peaks (60 min, 78%; 180 min, 60%) and spontaneous high amplitude spikes (60 min, 89%; 180 min, 80%) ( Fig. 4A and B , middle columns). However, synchronized epileptiform bursts were greatly reduced in 60 min pre-injection group (44%) and slightly reduced in 180 min group (60%) (Fig. 4C) . For those rats still showing some forms of CTZ-induced epileptiform bursts after K252a pre-injection, we further analyzed whether K252a altered the latency of the epileptiform activity after CTZ injection (Fig. 5 , middle columns). Pre-injection of K252a significantly increased the latency for subsequent CTZ-evoked triple PS peaks (CTZ alone, 22.2 AE 2.3 min; 60 min, 56.1 AE 4.0 min, n ¼ 7; 180 min, 54.7 AE 5.8 min, n ¼ 3; P < 0.001 for both 60 and 180 min groups), and for spontaneous high amplitude spikes (CTZ alone, 39.9 AE 2.8 min; 60 min, 69.7 AE 5.4 min, n ¼ 8; 180 min, 66.5 AE 2.2 min, n ¼ 4; P < 0.001 for both 60 and 180 min groups) ( Fig. 5A and B, middle columns) . Interestingly, the synchronized epileptiform bursts had a long latency after CTZ injection alone (85.5 AE 8.2 min, n ¼ 10), and K252a pre-injection tended to increase the latency for epileptiform bursts (60 min, 110.4 AE 6.4 min, n ¼ 4; 180 min, 96.5 AE 7.0 min, n ¼ 3) but without reaching a statistic significance (60 min, P ¼ 0.097; 180 min, P ¼ 0.50) (Fig. 5C ). These results suggest that CTZinduction of epileptiform activity is mediated by the activation of receptor tyrosine kinases, including TrkB receptors. Since K252a is a broad spectrum receptor tyrosine kinase inhibitor, in the next set of experiments we used more specific TrkB-receptor antibodies to investigate the role of TrkB receptors during CTZinduction of epileptiform activity. , and synchronized bursts (C) in all rats tested. If K252a was injected 60 or 180 min prior to the injection of CTZ, the anti-convulsant effect was less prominent, possibly due to the metabolism or clearance of the drug during the longer interval. Similarly, injection of TrkB antibody 30 min prior to the CTZ injection also showed stronger effect than the 60 min interval in inhibiting the percentage of rats with epileptiform activity.
Effects of TrkB antibody on CTZ-induced epileptiform activity in hippocampal CA1 neurons in vivo
TrkB-receptor specific antibody (TrkB antibody, Transduction Laboratories, BD Biosciences) was injected (1.25 mg in 5 ml, i.c.v.) in 2 groups with 30 and 60 min prior to CTZ (5 mmol) administration. In 30 min pre-injection group, TrkB antibody essentially inhibited all synchronized epileptiform bursts induced by CTZ, similar to that of K252a (Fig. 3D, in comparison with Fig. 3B ). However, when CTZ was injected after 60 min interval following TrkB antibody injection, the inhibitory effect of TrkB antibody was partially diminished, suggesting that TrkB antibody might have been significantly cleared from lateral ventricle or inactivated after 1 h (Fig. 3E) . Pooled data showed that the 30 min TrkB antibody pre-injection group had a modest decrease in the percentage of animals showing triple PS peaks and spontaneous spikes (both 63%), but 60 min pre-injection did not show significant effect (Fig. 4A and B, right columns) . In contrast, synchronized bursts were suppressed in all animals tested (n ¼ 8) in the 30 min pre-injection of TrkB antibody group, and about half (57%) of the animals in the 60 min pre-injection group (Fig. 4C, right columns) . Despite the presence of triple PS peaks and spontaneous spikes in most animals pre-injected with TrkB antibody, the latency was nevertheless significantly prolonged for these activities (Fig. 5, right columns) . In 30 min pre-injection group, TrkB antibody significantly increased the latency for triple PS peaks to 43.6 AE 6.2 min (n ¼ 5, P < 0.01) and spontaneous spikes to 76.5 AE 3.6 (n ¼ 5, P < 0.001). After 60 min pre-injection, the latency for triple PS peaks was still significantly increased (35.7 AE 2.5 min, n ¼ 6, P < 0.01), but not the latency for spontaneous spikes (50.8 AE 5.4 min, n ¼ 7, P ¼ 0.063) (Fig. 5A and B , right columns). The latency for the synchronized bursts, in the rats where bursts persisted, tended to be prolonged after 60 min pre-injection of TrkB antibody but without reaching statistic significance (114.8 AE 6.0 min, n ¼ 4, P ¼ 0.054) (Fig. 5C, right  column) . To understand the relationship between the latency for epileptiform bursts and triple peaks, we plotted the latency for epileptiform bursts against the latency for triple peaks (Fig. 5D) . It is clearly shown that the latency for epileptiform bursts is much longer than the latency for triple peaks, and both are prolonged by TrkB IgG and K252a. Injection of TrkB antibody (1.25 mg in 5 ml, i.c.v.) alone did not induce any spontaneous activity in all 4 rats tested.
Because some animals showed CTZ-induced synchronized epileptiform bursts in the 60 min pre-injection groups of K252a or TrkB antibody, we have further quantified the frequency and duration of bursts in control and testing groups (Fig. 6) . The injection of CTZ alone at two different doses, 1 and 5 mmol, induced synchronized bursts at a similar frequency (1 mmol, 1.98 AE 0.42/ 10 min, n ¼ 5; 5 mmol, 2.76 AE 0.36/10 min, n ¼ 10) and duration (1 mmol, 16.7 AE 3.2 s; 5 mmol, 19.0 AE 1.3 s) ( Fig. 6A and B , left columns). Pre-injection of K252a (60 min) significantly reduced CTZ (5 mmol) evoked burst frequency (1.26 AE 0.18/10 min, n ¼ 4, P < 0.05) and burst duration (8.8 AE 0.6 s, n ¼ 4, P < 0.01) (Fig. 6A and B, middle column). The inhibitory effects of TrkB antibody were modest comparing to K252a, with a modest decrease in the burst frequency (1.68 AE 0.30 Hz, n ¼ 4, P ¼ 0.11) but a significant decrease in the burst duration (11.6 AE 1.1 s, n ¼ 4, P < 0.01) (Fig. 6A and B , right column).
Together, our results demonstrate that BDNF-TrkB signaling pathway is critically involved in the CTZ-induction of epileptiform activity in in vivo conditions.
Effects of K252a and TrkB antibody on CTZ-induced epileptiform activity in cultured hippocampal neurons
We further employed in vitro hippocampal cultures to investigate the effects of K252a and TrkB antibody on epileptiform bursts at the single cell level. Previous work from our lab has reported that CTZ treatment of hippocampal cultures induced robust epileptiform bursts (Qi et al., 2006a) . In the first set of experiments, K252a (500 nM) or TrkB-receptor specific antibody (5 mg/ml) was added together with CTZ (5 mM) during chronic treatment (48 h). After 48 h-treatment, all drugs were washed away and neuronal activity was examined with whole-cell patch clamp recordings in normal bath solution. CTZ treatment alone induced robust epileptiform activity as reported before (Fig. 7A ) (Qi et al., 2006a) . However, K252a þ CTZ or TrkB antibody þ CTZ both resulted in a significant attenuation of epileptiform activity (Fig. 7B and C) . The percentage of neurons displaying epileptiform activity was reduced from 85.7% with CTZ alone to about half with K252a þ CTZ (40.9%) and one third of the control with TrkB antibody þ CTZ (26.7%) (Fig. 7D) . Among those neurons which did show epileptiform activity with K252a or TrkB antibody chronic treatment, the frequency of epileptiform bursts was also significantly reduced (CTZ alone, 0.13 AE 0.02 Hz; K252a þ CTZ, 0.026 AE 0.006 Hz, p < 0.001; TrkB antibody þ CTZ, 0.058 AE 0.009 Hz, P < 0.01) (Fig. 7E) . In addition to chronic treatment, we also tested whether acute treatment of TrkB antibody has any effect on epileptiform activity. Hippocampal cultures were pretreated with TrkB IgG (5 mg/ml) for 1 h before treating with CTZ (20 mM) for 2 h. After the treatment, coverslips were transferred to recording chamber for experiments in normal bath solution. We found that acute treatment of TrkB IgG significantly inhibited the epileptiform burst frequency induced by CTZ (CTZ alone, 0.038 AE 0.01 Hz, n ¼ 8; CTZ þ TrkB IgG, 0.017 AE 0.006 Hz, n ¼ 9; P < 0.002). These in vitro data in hippocampal cultures are consistent with our in vivo experimental results, suggesting an important role of BDNF-TrkB signaling in CTZ-induction of epileptiform activity.
We next tested the acute effect of K252a on chronic or acute CTZ treatment-induced epileptiform activity. Acute application of K252a (500 nM) showed a direct inhibitory effect on the epileptiform activity already established by chronic or acute CTZ treatment (Fig. 8) . We demonstrate here that long-term treatment (7 days) of hippocampal cultures with CTZ (20 mM) resulted in robust epileptiform bursts similar to that with 2-day treatment reported before (Qi et al., 2006a) (Fig. 8A, n ¼ 4) . Acute bath application of K252a abolished most of the epileptiform bursts (Fig. 8B) . Similarly, acute application of K252a (500 nM) also inhibited the epileptiform bursts induced by acute CTZ treatment (20 mM, 2 h) (Fig. 8C) .
One interesting observation arising from our K252a experiments is that action potentials associated with epileptiform bursts appeared to be inhibited in the presence of K252a but spontaneous synaptic potentials or currents persisted ( Fig. 8B  and C) . Therefore, we decided to investigate whether K252a has any direct effect on the basal neuronal activity in hippocampal cultures without CTZ treatment. Interestingly, bath application of 250 nM K252a significantly decreased the action potential firing frequency in all of the neurons recorded (Fig. 9A , n ¼ 7; control, 0.98 AE 0.28 Hz; during K252a, 0.31 AE 0.17; P < 0.001, paired t test). The application of higher concentration of 500 nM K252a further suppressed the action potential firing and in some neurons even completely blocked action potentials (Fig. 9B , n ¼ 4). This inhibitory effect is readily reversible after washing off K252a. The precise mechanism underlying the K252a inhibition of action potential firing is currently under further study. Preliminary experiments did not find such inhibition of action potentials in the presence of TrkB antibodies, suggesting that K252a has unique effect on action potential firing that is likely beyond its effect on TrkB receptors.
Discussion
In this work we have demonstrated that BDNF-TrkB signaling pathway plays a critical role in mediating the induction of or TrkB antibody 60 min prior to CTZ injection both shortened the duration of synchronized bursts. *P < 0.05, **P < 0.01 and ***P < 0.001 in comparison with those of injecting CTZ alone. Note that pre-treatment with K252a or TrkB antibody 30 min prior to CTZ injection totally prevented the synchronized bursts (see Fig. 5 ).
epileptiform activity by CTZ. Intracerebroventricular injection of CTZ induces progression of epileptiform bursts, starting from an early onset of multiple evoked PS peaks, to highly synchronized epileptiform bursts within 180 min. Infusion of receptor tyrosine kinase inhibitor K252a or specific TrkB-receptor antibody essentially abolished the epileptiform bursts induced by CTZ. Similarly, in cultured hippocampal neurons, chronic or acute application of K252a or TrkB IgG together with CTZ significantly inhibited the epileptiform bursts induced by CTZ. Our results support that BDNFTrkB signaling is a common pathway during epileptogenesis.
CTZ is a potent convulsant inducing epileptiform bursts in hippocampal neurons
The i.c.v. administration of CTZ induces epileptiform bursts in a dose-dependent manner in urethane anaesthetized rats. Multiple peaks of PSs, a traditional determinant of epileptogenesis, have been observed in 100% of animals after the injection of CTZ. In addition, spontaneous seizure-like activity occurred in 50% of animals administered with 1 mmol and w80% of animals dosed with 5 mmol CTZ. Such prompt seizure activity was comprised of high amplitude and high frequency synchronized burst firing, exhibiting much similarity to both pentylenetetrazole and KA models as well as human temporal lobe epilepsy (Avoli et al., 2002 (Avoli et al., , 2005 . Before the high frequency synchronized bursting activity, there were low frequency (w1 Hz), high amplitude individual spikes spontaneously occurring. Thus, in vivo recordings from anaesthetized rats showed that, after i.c.v. injection of CTZ, there was a time-dependent progression of epileptiform bursts, from the multiple PS peaks to spontaneous individual spiking, to final highly synchronized burst firing. The long delay of the synchronized bursts (80-100 min) suggests that neuronal activity has to reach certain threshold before being abnormally synchronized. On the other hand, the delay for the synchronization appears to be less dose-dependent. Although CTZ injection at higher dose (5 mmol)
induced triple peaks PSs with a much shorter latency (w20 min) than the low dose (1 mmol, latency >50 min), the latency for epileptiform bursts at both doses was about 80-100 min, with no statistical difference (Fig. 2B) . Furthermore, the burst frequency and the burst duration were also similar between the 1 and 5 mmol doses (Fig. 6) . These results suggest that the formation of epileptiform bursts depends on certain activity threshold. Once surpassing the threshold, the network activity will be synchronized according to its intrinsic properties regardless of the initial dose of convulsant drugs.
It is noteworthy to point out that although CTZ is a potent convulsant drug as we have reported before (Qi et al., 2006a) , our initial experimentation with subcutaneous (50 mg kg injection of CTZ produced neither evoked multiple PS peaks nor spontaneous burst firing in all of the animals tested. In contrast, our later experiments with i.c.v. administration of CTZ, as presented in the current study, showed that CTZ can induce epileptiform bursts. These results suggest that CTZ, once prescribed as a clinical anti-hypertension drug, is not capable of passing through blood-brain barrier. This is perhaps why such epileptic side effect of CTZ was not reported in previous clinical trials.
Blocking receptor tyrosine kinases and BDNF-TrkB pathway on CTZ-induced epileptiform bursts
Our findings that blocking TrkB receptors abolished the induction of epileptiform activity by CTZ, a convulsant identified in our lab, suggest that BDNF-TrkB signaling is likely a common pathway involved in many different epilepsy models (Binder et al., 2001) . We found that the time interval between the pre-injection of K252a or TrkB antibody and the injection of CTZ is critical for the suppression of epileptiform bursts. If CTZ was injected within 30 min after blocking TrkB receptors, no epileptiform bursts can be elicited by CTZ. However, if CTZ was injected 60 min after pre-injection of K252a or TrkB antibody, about half of animals still displayed epileptiform bursts, suggesting that the blocking effect on TrkB receptors has been partially relieved within 60 min. Therefore, the metabolic rate of K252a or TrkB antibody in the cerebroventricules is somewhere between 30 and 60 min. We also noticed that the inhibitory effect of K252a is more potent than TrkB antibody in terms of suppressing multiple peaks of PSs and spontaneous spiking events. Although drug doses may be a contributing factor, the fact that K252a inhibits not only TrkB receptors but also other receptor tyrosine kinases suggests that signaling pathways other than BDNF-TrkB may also play a role in regulating neuronal activity and epileptiform bursts.
Common properties of BDNF and CTZ in regulating neural activity
It is interesting to note that BDNF potentiates glutamatergic neurotransmission but in the mean time inhibits GABAergic neurotransmission (Kang and Schuman, 1995; Tanaka et al., 1997; Binder et al., 2001; Zhu and Roper, 2001) . Similarly, we have demonstrated that CTZ also has such dual effects in enhancing glutamatergic neurotransmission and depressing GABAergic neurotransmission (Deng and Chen, 2003) . It is thus not a coincidence that both BDNF and CTZ have been found to be able to induce epileptiform bursts (Scharfman et al., 2002; Qi et al., 2006a) . However, the acting mechanisms are distinctly different between BDNF and CTZ. BDNF acts by binding with TrkB receptors and activate down-stream protein kinases to phosphorylate substrates, leading to increased presynaptic release probability or changes in postsynaptic receptor function (Binder and Scharfman, 2004; Binder, 2007) . Rapid application of BDNF to neurons can cause direct membrane depolarization or even firing of action potentials (Kafitz et al., 1999; Rose et al., 2004) . In contrast, application of CTZ alone does not activate ion channels or receptors directly (Deng and Chen, 2003; Qi et al., 2006a) . Instead, CTZ acts as a modulator by prolonging AMPA receptor responses or inhibiting GABA A receptor responses (Qi et al., 2006a) . Despite the fundamental differences in their acting mechanisms, both BDNF and CTZ can substantially increase neural activity by positive regulation of glutamatergic and negative regulation of GABAergic neurotransmission. Our present study further suggests that the BDNF receptor TrkB is essential for CTZ-induction of epileptiform activity. Together, we propose that CTZ-induced initial increase of neuronal activity may trigger BDNF release, which activates TrkB receptors and further increases neuronal activity. Such positive feedback effects on neuronal activity may eventually lead to the formation of abnormally synchronized epileptiform bursts. 
